Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma

Yang Liu, Weiming Mao

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma.

Original languageEnglish (US)
Pages (from-to)7-14
Number of pages8
JournalClinical Ophthalmology
Volume7
Issue number1
StatePublished - Dec 20 2012
Externally publishedYes

Fingerprint

Open Angle Glaucoma
Intraocular Pressure
Synthetic Prostaglandins
Patient Compliance
Glaucoma
Therapeutics
Safety
tafluprost

Keywords

  • Glaucoma
  • Intraocular pressure
  • Preservative-free formulation
  • Prostaglandin analog
  • Tafluprost

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma. / Liu, Yang; Mao, Weiming.

In: Clinical Ophthalmology, Vol. 7, No. 1, 20.12.2012, p. 7-14.

Research output: Contribution to journalReview article

@article{fd324a5872a34c28a04ef2f52f97a659,
title = "Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma",
abstract = "Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma.",
keywords = "Glaucoma, Intraocular pressure, Preservative-free formulation, Prostaglandin analog, Tafluprost",
author = "Yang Liu and Weiming Mao",
year = "2012",
month = "12",
day = "20",
language = "English (US)",
volume = "7",
pages = "7--14",
journal = "Clinical Ophthalmology",
issn = "1177-5467",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma

AU - Liu, Yang

AU - Mao, Weiming

PY - 2012/12/20

Y1 - 2012/12/20

N2 - Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma.

AB - Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma.

KW - Glaucoma

KW - Intraocular pressure

KW - Preservative-free formulation

KW - Prostaglandin analog

KW - Tafluprost

UR - http://www.scopus.com/inward/record.url?scp=84871628183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871628183&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84871628183

VL - 7

SP - 7

EP - 14

JO - Clinical Ophthalmology

JF - Clinical Ophthalmology

SN - 1177-5467

IS - 1

ER -